Inozyme Pharma specializes in developing treatments for rare diseases affecting vasculature, soft tissue, and skeleton. Their lead product, INZ-701, targets ENPP1 and ABCC6 deficiencies and end-stage kidney disease patients.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing